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IsonicotinoylhydrazoneAbstract Orthohydroxypropiophenoneisonicotinoylhydrazone ligand(L) has been synthesized
from orthohydroxypropiophenone and isonicotinicacid hydrazide. The Cu(II) complex is prepared
and structurally characterized. The structure of the ligand(L) is proposed based on elemental anal-
ysis, IR and mass spectra and Cu(II) complex is characterized from the studies of electronic spectra,
EPR spectra, powder X-ray diffraction (XRD) and scanning electron microscopy (SEM). On the
basis of electronic and EPR studies, rhombically distorted octahedral environment has been pro-
posed for the Cu(II) ion. The powder X-ray diffraction data indicate triclinic structure with the unit
cell parameters: a = 9.4734 A˚, b= 6.1588 A˚, c= 3.9254 A˚, and V= 195.6 A˚3 for the complex.
The ligand and Cu(II) complex have been tested for in vitro antibacterial, antioxidant and cytotoxic
activities. The results reveal that the Cu(II) complex exhibits greater activity than the free ligand.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Interest in the study of hydrazones has been growing because
of their antimicrobial, antituberculosis and antitumour activi-
ties (Chohan and Sheazi, 1999; Jayabalakrishnan and Natara-
jan, 2001; Jeeworth et al., 2000; Zhi-hong et al., 2008).
Hydrazones play an important role in inorganic chemistry,
as they easily form stable complexes with most of the transi-
tion metal ions. The development in the ﬁeld of bioinorganic
chemistry has increased the interest in hydrazone complexes,
since it has been recognized that many of these complexes
Synthesis, spectroscopic and anti tumor studies on copper(II) S405may serve as models for biologically important species (Wan-yi
et al., 2001). Coordination compounds derived from aryl
hydrazones have been reported to act as enzyme inhibitors
and are useful due to their pharmacological applications
(Narang and Singh, 1993; Savanini et al., 2002; Ochiai and
Ei-ichiro, 1977). Hydrazones possessing an azomethine
ANHN‚CHA proton constitute an important class of com-
pounds for new drug development. Therefore, many research-
ers have synthesized these compounds as target structures and
evaluated their biological activities. Hydrazones and their me-
tal complexes are biologically very active compounds. Maria et
al. (2007) have reported the antibacterial activities of cobal-
t(II), copper(II), nickel(II), and zinc(II) complexes of 2-thio-
phenecarbonyl hydrazone and isonicotinoylhydrazone of
3-(N-methyl)isatin-2-thiophene carbonyl metal complexes ex-
hibit a strong inhibition on the growth ofHaemophilus infrenza
and good antibacterial activity toward Bacillus subtilis.
2. Experimental
2.1. Materials
All the chemicals used are of analytical grade. Organic chem-
icals, such as thiobarbituric acid (TBA), trichloroacetic acid
(TCA), a-tocopherol, butylated hydroxy toulene (BHT),
1,1-diphenyl-2-picryl hydrazyl (DPPH), isonicotinicacid
hydrazide, and dimethyl formamide (DMF) are procured
from Sigma–Aldrich and all metal salts are procured from
E. Merck.
2.2. General procedures
The IR spectra of the compounds are recorded on a Nicolet
FT-IR 560 Magna spectrometer using KBr (Pellet). Mass spec-
tra are recorded in a Quattro LC, Micro Mass spectrometry.
Elemental analysis is obtained from a Vario-Micro Qub ele-
mentar analyzer. The electronic spectra of the complexes are
recorded on a Perkin Elmer UV/VIS Lambda 950. EPR spec-
tra are recorded on an EPR spectrometer (JEOL FE-1X) oper-
ating in the X-band frequencies with a modulation frequency
of 100 kHz. Samples of 100 mg are taken in a quartz tube
for EPR measurements. The magnetic ﬁeld is scanned from
2200 to 4200 G, with a scan speed of 250 G min1. Absorbance
is measured using Systronics UV–VIS spectrometer-117.
Centrifugation is done using REMI centrifuge. A digital pH
meter (model L1-10 Elico, India) is used for measuring pH.
X-ray diffractometer (PHILIPSPW3710) using CuKa
(1.5418 A˚) radiation operated at 45 kV and 25 mA is used in
X-ray investigations.
2.3. Synthesis of free ligand(L)
Approximately 15 ml (0.1 M) of orthohydroxypropiophenone
is dissolved in 150 ml of methanol and 0.1 M (13.7 g) of
isonicotinicacid hydrazide is dissolved in 150 ml of water. The
two solutions are taken in a 500 ml round bottomed ﬂask, two
pellets of sodium hydroxide are added and reﬂuxed for two
hours on a water bath. The resultant product Orthohydroxy
propiophenoneisonicotinoylhydrazone(L) is ﬁltered, washed
with water and methanol. It is recrystallised using aqueous
methanol and dried.2.4. Synthesis of metal complex
A methanolic solution of copper(II) chloride (0.001 M and
25 ml MeOH) is added to a methanol solution of free ligand
(0.001 M and 25 ml MeOH). The reaction mixture is reﬂuxed
on water bath for 3–4 h at 70 C. On cooling the contents, the
colored complex is precipitated, ﬁltered, washed with 50%
ethanol and dried. The purity of the complex is checked byTLC.
2.5. Antibacterial screening
In vitro antibacterial screening is performed by the agar disc
diffusion method (Bauer et al., 1966; Sheikh et al., 2004).
The bacterial species used in the screening are gram-negative
bacteria such as Klebsiella pneumoniae and Escherichia coli
and gram-positive bacteria such as Staphylococcus aureus
and B. subtilis. Stock cultures of the test bacterial species are
maintained on nutrient agar media (Hi-media laboratories,
Mumbai) by sub culturing in Petri dishes. The media are pre-
pared by adding the components as per manufacturer’s
instructions and sterilized in the autoclave at 121 C and atmo-
spheric pressure for 15 min. Each medium is cooled to 45–
60 C and 20 ml of it is poured into a Petri dish and allowed
to solidify. After solidiﬁcation, Petri plates with media are
spread with 1.0 ml of bacterial suspension prepared in sterile
distilled water. The wells are bored with cork borer and the
agar plugs are removed. To each agar well, 100 ml of the com-
pound reconstituted in DMF of concentration 1.0 mg/ml is
added. DMF is used as a negative control and in a similar
way, antibiotics, such as ampicillin and tetracycline are used
as positive control standards. All the plates are incubated at
37 C for 24 h and they are observed for the growth inhibition
zones. The presence of clear zones around the wells indicate
that both the ligand and complex are active. The diameter of
zone of inhibition is calculated in millimeters. The well diame-
ter is deducted from the zone diameter to get the actual zone of
inhibition diameter and the values are tabulated.
2.6. DPPH scavenging activity
The principle for the reduction in DPPH free radicals is that
the antioxidant reacts with stable free radical DPPH and con-
verts it to 1,1-diphenyl-2-picrylhydrazine. The ability to scav-
enge the stable free radical DPPH is measured by a decrease
in the absorbance at 517 nm. Solutions of ligand and Cu(II)
complex at 100 lM concentration are added to 100 lMDPPH
and kept in ethanol tubes. The tubes are kept at ambient tem-
perature for 20 min and absorbances are measured at 517 nm.
For positive control, a-tocopherol is used (Balige et al., 2004).
These measurements are run in triplicate. The percentage of
scavenging activity is calculated as follows:
Scavenging activity ð%Þ ¼ ½ðADPPH  ATESTÞ=ADPPH  100
where ADPPH is the absorbance of DPPH without test sample
(control) and ATEST is the absorbance of DPPH in the presence
of test sample.
2.7. Inhibition of lipid peroxidation in rat brain homogenate
2.7.1. Preparation of rat brain homogenate
For the present study, Albino Wistar rats (180–200 g) are
selected. Prior to decapitation and removal of the brain, the
S406 G.N. Ramesh et al.animals are anesthetized with ether and perfused transcardially
with ice-cold normal saline to prevent contamination of the
brain tissue with blood. The collected tissues are weighed
and their homogenates (10% w/v) are prepared in 0.15 M
KCl and centrifuged at 800 rpm for 10 min. The supernatants
are used immediately for the study (Bharathi et al., 2008).
2.7.2. Iron(III) induced lipid peroxidation
The incubation mixtures contain a ﬁnal volume of 1.5 ml brain
homogenate (0.5 ml) of 10% w/v), KCl (0.15 M) and ethanol
(10 ll) or test compound dissolved in ethanol. Peroxidation
is initiated by adding ferric chloride (100 lM) to give the ﬁnal
concentration stated. After incubation for 20 min at 37 C,
reactions are stopped by adding 2 ml of ice-cold 0.25 M HCl
containing 15% trichloroaceticacid (TCA), 0.38%. thiobarbi-
turic acid (TBA) and 0.05% butylated hydroxy toulene
(BHT). The samples are heated at 80 C for 15 min, cooled
and centrifuged at 1000 rpm for 10 min. The absorbances of
the supernatant solutions are measured at 532 nm. Percentage
inhibition of thiobarbituricacid reactive substances (TBARS)
formed by test compounds is calculated by comparing with
the control. Iron(III) and KCl solutions are prepared afresh
in distilled water. Since most buffers trap hydroxyl radical or
interfere with iron conversion, the reactions are carried out
in unbuffered 0.15 M KCl solution (Jayan and Rao, 1994;
Braughler et al., 1988).
The inhibition percentages of the selected ligand and Cu(II)
complex are evaluated using lipid peroxidation method. The
following formula is used in calculating inhibition percentages.
Inhibition percentage ¼ ½ðACONT  ATESTÞ=ACONT  100
Here, ACONT is the absorbance of the control reaction and
ATEST is the absorbance in the presence of the test sample.Figure 1 Mass spectrum of the ligand.2.8. Determination of cytotoxicity of compounds to EAC cells
tryphan blue exclusion method (cell viability test)
In vitro short-term cytotoxic activity of drug is determined
using EAC cells. The EAC cells that are collected from
the animal peritoneum by aspiration are washed repeatedly
with PBS to free it from blood. After checking the viability
of the cells in a hemocytometer, the cells (1 · 106) in 0.1 ml
PBS, 0.01 ml of various concentrations of test compounds
(10–100 lg/ml) are made (the test compounds are dissolved
in dimethyl sulfoxide (DMSO). The ﬁnal concentration of
DMSO not exceeding 0.1% of the total volume) and phos-
phate buffered saline (0.1 mole/l, pH = 7) in a total volume
of 0.9 ml are incubated in clean sterile tubes for 3 h at
37 C. The control tube has 10 ll of solvent. The ﬁnal vol-
ume is made up to 0.9 ml with PBS. To each 100 ll of try-
phan blue solution is added. The live (without stain) and
dead (with blue stain) cells are counted using hemocytometer
and percentage of cell death was calculated using the
formula:
% Cytotoxicity ¼ 100 ðTdead  CdeadÞ=Ttot
where, Tdead is the no. of dead cells in the treated group, Cdead
is that in the control group, and Ttot is the total number of
dead and live cells in the test compound treated in the group.
Cisplatin is used Cisplatin was used as a standard (Devi et al.,
1994).3. Results and discussion
3.1. Characterization of ligand
It is a pale yellow crystalline solid and melts at 248–250 C.
The yield is about 86%. The ligand is analyzed by IR and mass
spectroscopy. The IR spectrum of ligand exhibits absorption
bands around 1600 cm1 (C‚N), 1680 cm1 (C‚O) and
3140 cm1(ANH). Elemental analysis gives C 66.39%, H
5.43%, N 15.34% Calculated C 66.91% H 5.58% N 15.61%.
The mass spectrum of ligand (Fig. 1) shows a molecular ion
(M+) peak at m/z value of 269, corresponding to the species
C15H15N3O2. These spectral data conﬁrm the proposed
formula of the ligand C15H15N3O2. These data conﬁrm the
formation of ligand Orthohydroxypropiophenoneisonicotino-
ylhydrazone(L) which is presented in Scheme. 1.
3.2. Electron paramagnetic spectrum of the Cu(II) complex
The EPR spectrum of the Cu(II) complex recorded at room
temperature with polycrystalline sample is shown in (Fig. 2),
It consists of three lines each in the low ﬁeld (g1), mid ﬁeld
(g2) and high ﬁeld (g3) regions. From the peaks’ positions
and their separations, the g-values evaluated are g1 = 2.444,
g2 = 2.178, and g3 = 2.031. From the data, information on
the electronic ground state of Cu(II) can easily be inferred.
For the g-values g1 > g2 > g3, if the quantity {R= (g2 
g3)/(g1  g2)} is greater than one, the ground state is predom-
inantly 2A1 (d
2
z ) and if R is less than unity, the ground state is
2A1(dx2y2). In the present study the value R is found to be of
the order 0.55, i.e. less than unity, indicating that the ground
state is 2A1(dx2y2).
3.3. Electronic spectrum of the Cu(II) complex
The electronic spectrum(optical absorption) of Cu(II) complex
shown in (Fig. 3) exhibits four bands at 1284, 1119, 853 and
803 nm, characteristic of rhombic distortion with the general
order of the energy levels as 2A1(dx2y2) < 2A1(dz2) < 2A2
(dxy) <
2B1(dxz) <
2B2(dyz). The optical absorption bands
observed at room temperature are assigned as follows:
1284 nm (7788 cm1): 2A1(dx2y2)ﬁ 2A1(dz2), 1119 nm
(8937 cm1): 2A1(dx2y2)ﬁ 2A2(dxy), 853 nm (11,723 cm1):
2A1(dx2y2)ﬁ 2B1(dXZ) and 803 nm (12,453 cm1): 2A1(dx2-y2)
ﬁ 2B2(dyz), respectively. These observations are in tune with
those reported earlier and the bands are accordingly ascribed
to Cu(II) complex in octahedral coordination with rhombic
Scheme 1 Synthesis and structure of ligand.
Figure 2 Powder X-band EPR spectrum of Cu(II) complex at
room temperature (m= 9.205 GHz).
Scheme 2 The Proposed structure of Cu(II) complex.
Synthesis, spectroscopic and anti tumor studies on copper(II) S407(C2v) distortion. Based on the spectral studies the following
structure is proposed for the Cu(II) complex(Scheme. 2).
3.4. Surface morphological studies
Powder X-ray diffractograph of Cu(II) complex are depicted
in Fig. 4. The observed and calculated diffraction data are
given in Table 1. Using the trial and error method the unit cellFigure 3 Electronic spectrumparameters of Cu(II) complex are found to be a= 9.4734 A˚,
b= 6.1588 A˚, c= 3.9254 A˚, a= 109.497, b= 108.040,
c= 99.642 and unit cell volume V= 195.6 A˚3. These data
of the Cu(II) complex support the triclinic system. The
observed X-ray pattern of the free ligand sample studied in
the present investigation indicates amorphous nature. To eval-
uate the crystallite size of the synthesized Cu(II) complex, D is
determined using Debye–Scherer formula (Warren, 1990)
given by
D ¼ 0:94k
b cos h
where b is the full width at half maximum of the predomi-
nant peak and h is the diffraction angle and k is the wave-(nm) of Cu(II) complex.
Figure 4 XRD spectrum of Cu(II)complex.
Table 1 Powder X-ray diffraction data of Cu(II) complex.
d-spacing (A˚) 2h values D2h (hkl)
Observed calculated Observed calculated
5.5342 5.5342 16.00 16.00 0.000 (0 1 0)
5.4640 5.4640 16.21 16.21 0.000 ð110Þ
4.1193 4.1193 21.55 21.55 0.000 (1 1 0)
3.7003 3.7003 24.03 24.03 0.000 ðbar101Þ
2.8072 2.8072 31.85 31.85 0.000 (1 0 1)
2.7050 2.7050 33.09 33.09 0.000 ð111Þ
2.5364 2.3518 35.36 35.28 0.77 ð311Þ
2.3523 2.3514 38.23 38.24 0.015 ð221Þ
2.2587 2.2606 39.88 39.84 0.036 ð401Þ
2.0378 2.0410 44.42 44.34 0.072 ð311Þ
1.9947 1.9940 45.43 45.45 0.016 ð131Þ
1.8582 1.8586 48.97 48.97 0.011 ð312Þ
1.8236 1.8241 49.97 49.95 0.014 (4 1 0)
1.8028 1.8015 50.59 50.59 0.039 ð510Þ
1.6944 1.6922 54.08 54.15 0.076 ð411Þ
1.6314 1.6327 56.35 56.30 0.050 ð132Þ
1.4627 1.4617 63.55 63.60 0.049 ð431Þ
1.3983 1.3984 66.85 66.84 0.005 (0 3 1)
1.3578 1.3536 69.12 69.37 0.250 (1 1 2)
S408 G.N. Ramesh et al.length of light. The sizes of the crystallites of the Cu(II)
complex are found to be of the order of 60 nm. The SEM
micrographs of the Cu(II) complex are shown in (Fig. 5).
The SEM image of Cu(II) complex consists of a cauliﬂower
shaped particle.
3.5. Antibacterial activity
The in vitro antibacterial properties of the free ligand and
Cu(II) complex are evaluated against gram-negative and
gram-positive bacteria. The obtained results are reported in
Table 2. The Cu(II) complex shows higher antibacterial
activity than that of free ligand. It is evident that Cu(II)metal chelate exhibits effective antibacterial activities. The
increased activity of the metal chelate can be explained on
the basis of chelation theory (Sengupta et al., 1998). It is
known that chelation tends to make the ligand more power-
ful and exhibits more antibacterial activity than the ligand.
It is observed that in a complex, the positive charge of the
metal is partially shared with the donor atoms present in
the ligand and there may be g-electron delocalization over
the whole chelating.
The synthesized ligand and Cu(II) complex have been
screened for reduction in DPPH free radicals and inhibition
of iron(III) induced lipid peroxidation at 100 lm concentra-
tion. The Cu(II) complex shows good activity in DPPH scav-
enging (33%) and ferric ion induced lipid peroxidation
(45%) as seen in the case of standard antioxidant a-tocoph-
erol, but free ligand shows low activity against DPPH scaveng-
ing and ferric ion induced lipid peroxidation. Relevant data are
presented in Table 3.
3.6. Tryphan blue exclusion method (cell viability test)
The compounds are tested using the short term in vitro cyto-
toxicity toward EAC (Ehrlich Ascites Carcinoma) cells as a
preliminary screening technique of tryphan Blue exclusion
method (cell viability test) for their cytotoxic potential (Devi
et al., 1998). This is one of the methods to assess cytotoxic-
ity of anticancer compounds. This test is based on the
principle that living cell membrane has the ability to prevent
the entry of a dye. Hence, they remain unstained and can be
easily distinguished from dead cells, which take the dye.
Thus the percentage of viable cells can be determined.
Results of the short term in vitro cytotoxicity of the
compounds are shown in Table 4. These preliminary exper-
iments are carried out mainly with three different concentra-
tions of the compounds. At 100 lg/ml concentration the
standard (Cisplatin) shows 80% cell death. At that same
concentration the Cu(II) complex shows (61%) cell death.
Figure 5 The SEM image of Cu(II) complex.
Table 2 Antibacterial screening data of the ligand and Cu(II)
complex (Diameter of Zone of Inhibition in mm).
Compound K. Pnuemoniae E. Coli B. Subtilis S. aureus
Ligand(L) 06 14 08 –
Cu(II) complex 22 25 18 20
Ampicillin 43 40 43 42
Tetracycline 32 33 30 32
Table 3 Effect of ligand and Cu(II) complex on scavenging of
DPPH and Fe3+ induced lipid peroxidation at 100 lM
concentration.
Compound DPPH
scavenging (%)
Fe+3 induced
lipid peroxidation
Ligand(L) 22 30
Cu(II) complex 33 45
a-Tocopherol 53 65
Table 4 Short-term in vitro Cytotoxicity of ligand and its
Cu(II) complex toward EAC cells.
Compound Percentage of cell-death at diﬀerent concentrations
after 3 h
10
lg/ml
50
lg/ml
100
lg/ml
LC50
lg/ml
Ligand(L) 15 14 31 2342.57
Cu(II)
complex
35 45 61 49.47
Cisplatin 14 25 80 42.45
Synthesis, spectroscopic and anti tumor studies on copper(II) S409The Cu(II) complex is found to have considerable cytotoxic-
ity in the cell viability test.4. Conclusions
In the present work, coordination chemistry of ligand, ob-
tained from the reaction of orthohydroxypropiophenone and
isonicotinicacid hydrazide is described. The Cu(II) complex
has been synthesized using the ligand and characterized on
the basis of analytical and spectral data. The EPR and elec-
tronic spectral studies suggest that Cu (II) complex has a
rhombically distorted octahedral environment for Cu(II) with
2A1g (dx
2  y2) as the ground state and powder X-ray diffrac-
tion suggests triclinic structure of the complex. Upon complex-
ation with metal ions particularly for Cu(II), the antibacterial
activity of the ligand is enhanced against four bacteria (B. sub-
tilis, S. aureus, E. coli and, K. pneumonia). The synthesized li-
gand and Cu(II) complex are screened for reduction of DPPH
and inhibition of iron induced lipid per oxidation at 100 lM
concentration. Among them, Cu(II) complex shows good
activity in DPPH scavenging (33%) and ferric ion induced li-
pid per oxidation (45%) as seen in the case of standard antiox-
idant a-tocopherol, but free ligand shows low activity against
DPPH scavenging and ferric ion induces lipid peroxidation.
The Cu(II) complex shows more in vitro cytotoxic activity than
free ligand. However, its in vitro cytotoxic activity can be fur-
ther conﬁrmed by in vivo methods.Acknowledgements
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